胃癌发生发展涉及多基因多靶点，常规疗效仍不理想。以阻断PD-L1/PD-1、HER2-PI3K等通路的多靶点治疗备受关注，但目前的单抗类靶向药物副作用大、成本高。有健脾化瘀功效的归芪白术方联合化疗治疗胃癌疗效明显，我们认为同时阻抑PD-L1/PD-1通路恢复T细胞活性、阻抑HER2-PI3K通路抑制胃癌细胞增殖是该方治疗胃癌的可能机制。本课题结合生物信息和已上市药物靶点，优选PD-L1/PD-1和HER2-PI3K主要靶点配伍，运用分子对接筛选复方中与上述靶点有效结合的小分子；基于PD-L1/PD-1和HER2-PI3K双通路不同靶点对小分子配伍，分别干预胃癌细胞与T细胞共培养体系及胃癌荷瘤小鼠；用激光共聚焦、流式细胞术、基因芯片等技术检测T细胞功能和胃癌细胞生物学性状，筛选最佳小分子配伍，基于“多点微调，协同增效”揭示该方促进免疫并抑制肿瘤的药效物质基础及健脾化瘀法治疗胃癌的分子机制。

The occurrence and development of gastric cancer involves multiple genes and multiple targets, and the conventional efficacy is still not ideal. Multi-target therapy for blocking PD-L1/PD-1, HER2-PI3K and other pathways has attracted much attention, but current monoclonal antibody-targeted drugs have large side effects and high cost. The Jianpi Huayu efficacy of Guiqi Baizhu Recipe combined with chemotherapy in the treatment of gastric cancer is obvious, it is believed that the possible mechanism is by suppressing PD-L1/PD-1 pathway to restore T cell activity and suppressing HER2-PI3K pathway to inhibit gastric cancer cell proliferation. This study focuses on PD-L1/PD-1 and HER2-PI3K pathways as the main targets by combining bio-informatics with marketed drug-targeted, using molecular docking to screen small molecules that effectively bind to the above targets; Different compounds formula based on PD-L1/ PD-1 and HER2-PI3K dual-channel different targets were used to intervene with gastric cancer cells and T cells co-culture system and gastric cancer-bearing mice. To screen for the best small molecule compatibility, laser confocal, flow cytometry, gene chip and other techniques are used to detect T cell function and biological characteristics of gastric cancer cells, which will reveal the pharmacological basis of Guiqi Baizhu Recipe in promoting immunity and inhibiting tumors, and the molecular mechanism of the treatment of gastric cancer with Jianpi Huayu formula based on "multi-point fine-tuning, synergistic synergy".